AACR22: After FerGene blowup, a startup touts even better bladder cancer gene therapy results in tiny study
A private California biotech is raising some eyebrows on the final day of AACR22 as it reported interim data for its experimental drug in combination with Keytruda.
Looking at 18 patients with non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette-Guérin (an FDA-approved agent for bladder carcinomas), CG Oncology found that 16 of the 18 achieved a complete response after just three months. On top of this, 13 maintained their response through six months, nine through nine months and eight after a year — the study’s primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.